Oxonol & MGM-15 Guide: 7-OH, DEA Status and MIT
Oxonol is a commercial product-line name, not the scientific name of a single alkaloid. The manufacturer currently describes Oxonol chewable tablets as a combination of MGM-15 and mitragynine. That distinction matters because the July 2026 federal record names MGM-15 directly, even though it does not use the brand name Oxonol.
Oxonol, MGM-15, and mitragynine are not interchangeable names
A front-label brand can remain the same while a formulation, strength, or package changes. An ingredient name is more specific. The manufacturer’s own description calls Oxonol a brand name and identifies MGM-15 and mitragynine as its active ingredients. DEA separately identifies MGM-15 as dihydro-7-hydroxymitragynine and describes it as a synthetic derivative of 7-hydroxymitragynine.
| Term | What it identifies | July 2026 federal record |
|---|---|---|
| Oxonol | A commercial brand/product-line name. Its manufacturer describes the tablets as containing MGM-15 plus mitragynine. | The brand name is not listed in DEA's notice; the named ingredient MGM-15 is. |
| MGM-15 | Dihydro-7-hydroxymitragynine, a synthetic derivative of 7-hydroxymitragynine. | Named in DEA's July 6 notice of intent for temporary Schedule I placement. |
| 7-OH | 7-hydroxymitragynine, which can occur at trace levels in botanical material and also appears in elevated or synthesized commercial products. | Covered by a separate July 2026 DEA notice with specified concentration thresholds. |
| MIT | Mitragynine, a naturally occurring alkaloid of Mitragyna speciosa. MIT extracts concentrate that named alkaloid. | Not one of the three MGM/pseudoindoxyl substances named in the MGM-15 notice. |
What the DEA notice says about MGM-15
DEA published a notice of intent on July 6, 2026 concerning MGM-15, mitragynine pseudoindoxyl, and MGM-16. The notice is not itself the temporary scheduling order. It says an order will not be issued before August 5, 2026 and will take effect on the date the order is published in the Federal Register. Until that later publication occurs, it is inaccurate to describe the intended temporary placement as already effective.
It is equally inaccurate to treat MGM-15 as outside the federal action simply because a package uses a brand name. Regulatory documents generally identify substances rather than every retail brand containing them. Read the ingredient panel and current formula alongside the current government document.
Why MIT belongs in a different product-identity lane
Mitragynine is a naturally occurring alkaloid of the kratom plant. DEA’s MGM-15 notice expressly contrasts naturally occurring mitragynine with MGM-15, MGM-16, and mitragynine pseudoindoxyl, which it describes as synthetic derivatives produced through chemical modifications of purified isolates. A concentrated MIT extract is still an extract and should be identified with its percentage, units, package size, and document scope, but MIT is not another name for MGM-15.
Kratom Paradise MIT tablets and MIT extract powder are presented around a named MIT product identity. Current tablet listings also explain the relationship to the 90% MIT-CH concentrate used as source material. That source-material record is not represented as a finished-tablet COA, and it does not turn the products into approved drugs or establish equivalence to 7-OH.
Five fields to check on an Oxonol or MGM-15 product
- Brand and manufacturer: record the company and exact product-line name.
- Ingredient identity: look for MGM-15, dihydro-7-hydroxymitragynine, mitragynine, 7-OH, pseudoindoxyl, or a mixture.
- Units and basis: keep milligrams per tablet, total package amount, percentage, and net weight separate.
- Formula date: product pages and packaging can change; save the version and date you reviewed.
- Regulatory date: distinguish a notice of intent from a later effective order, and check state and local rules separately.
Does “legal 7-OH alternative” settle the question?
No. “Legal” depends on the named substance, formula, place, and date. “Alternative” can describe a merchandising position without proving chemical identity, legal status, safety, or comparable effects. The July 2026 MGM-15 notice is especially important because older marketing may have been written before the notice appeared.
For the manufacturer’s description of the Oxonol name and formula, review its current product explainer. Treat that page as the seller’s own account, not independent scientific or legal confirmation.
Where to go next
Use our Oxonol vs MIT vs 7-OH comparison for a side-by-side identity check, the DEA 7-OH scheduling tracker for dated updates, and the MIT products guide for current tablet and powder formats.
This page is educational product and regulatory information, not medical or legal advice. Kratom Paradise does not sell Oxonol or MGM-15 products.